We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celartics Biopharma today announced that they have achieved major milestones and encouraging results in developing a new generation of mRNA vaccine, CA-R03, designed to prevent infection from SARS-COV-2 virus.